Thermo Fisher Scientific Debuts Innovation?s in Bioprocess?ing at INTERPHEX 2014
Thermo Fisher Scientific Inc., the world leader in serving science, has introduced new innovations in cell culture and bioprocessing technologies to address the evolving requirements of biologic drug discovery and production for global biopharmaceutical and pharmaceutical manufacturers. These advancements, including a new high-volume centrifugation system and controller platforms for its next-generation single-use bioreactor, will be showcased this week at INTERPHEX, Jacob Javitz Convention Center, New York City, 18–20 March 2014, Booth #3544.
“Thermo Fisher has combined exceptional technologies with a deep understanding of the challenges of bringing biologic pharmaceuticals from discovery to development and production,” said Cory Stevenson, president of the bioprocessing business at Thermo Fisher. “The combination of Thermo Scientific single-use technologies with the cell culture, purification, and analytics capabilities under the Life Technologies brand increases our depth of capabilities so that we can provide our biotechnology and biopharmaceutical customers with integrated solutions. Doing so enhances their efficiency and productivity across the entire bioproduction workflow.”
Highlights at INTERPHEX include
• New Thermo Scientific bioreactor controller platforms for the Thermo Scientific single-use systems offer the choice, performance and flexibility. Developed with technology integration partners Applikon and Finesse and under the Thermo Scientific brand, the controllers meet the needs of both highly configurable cGMP and cost-effective research applications.
• New Thermo Scientific Sorvall RC BIOS 10 large-capacity centrifuge offers a new 10-L capacity for batch bioprocessing centrifugation. The system combines the centrifuge with carbon fiber rotors and paperless data collection software, to improve productivity and protects sample safety and integrity.
• Life Technologies products that span the biologics workflow and include a portfolio of premium solutions and services focused on upstream cell culture, downstream purification and analytics for detection and quantitation of process/product impurities and contaminants. Products on display include Life Technologies Gibco cell culture media and feeds in both liquid and AGT Dry Media formats, GoPure Prepacked and POROS A, G and CaptureSelect Chromatography Columns, and MycoSEQ Myccoplasma Detection System.
• The industry-leading Thermo Scientific Aegis5-14 Film, the most advanced film for demanding cell culture and single-use bioprocessing applications.
• The Thermo Scientific HyPerforma Single-Use Bioreactor (SUB), which offers all of the advantages of previous SUBs while offering advancements that make it easier to manage tubing systems and loading of single-use Thermo Scientific bioprocess containers. The SUBs also feature faster heat up and cool down, flexible positioning, and height-adjustable single- or dual-filter brackets.
The combination of Thermo Scientific’s single-use and bioprocessing technologies with the cell culture, purification, and analytics business from Life Technologies increases our depth of capabilities so that we can provide our biotechnology and biopharmaceutical customers with integrated solutions across the entire bioproduction workflow.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...